DLPA 660 Ingredients & Drug Interactions
What is this page for?
First and foremost: checking DLPA 660 against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.
Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy
DLPA 660 is a dietary supplement by Earthborn Elements with 1 active ingredient. Its ingredients are commonly taken for depression and mood, skin condition vitiligo, pain conditions.Based on those ingredients, 16 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are DLPA. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.
Check Your Meds Against DLPA 660 by Earthborn Elements
Ask about any prescription or over-the-counter medication and we check it for interactions with DLPA 660 by Earthborn Elements — and tell you which ingredient is responsible.
AI summaries are generated from our interaction database for education only — always confirm with your pharmacist. How we use AI
Ask the Pharmacist
A licensed pharmacist will answer your question by email — free, usually within 24 hours.
Got it — thank you!
A licensed pharmacist will answer within 24 hours. Keep an eye on your email (worth checking spam, just in case).
HelloPharmacist Scorecard of DLPA 660 by Earthborn Elements
Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.
What’s inside
Full disclosure
This product contains one active ingredient: DLPA (a mix of D-phenylalanine and L-phenylalanine). The capsule itself is made with gelatin as an inactive ingredient.
Does it work?
Moderate evidence
Evidence for DLPA is mixed. The data supports it as possibly effective for vitiligo.
For ADHD, the evidence suggests it's possibly ineffective. For alcohol use disorder and multiple sclerosis, there isn't enough reliable evidence yet to rate how well it works.
How safe is it?
Well-documented data
DLPA is generally well tolerated at typical doses. The most common side effects are anxiety, constipation, headache, heartburn, insomnia, nausea, and sedation.
Do not use this supplement if you have PKU (phenylketonuria) — DLPA is unsafe for that condition. For pregnancy, safety data on supplement doses has not been established, so avoid it during that time.
While breastfeeding, lack of safety data means you should avoid supplement doses as well.
Meds to double-check
Major interaction found
Check with your pharmacist before using DLPA if you take levodopa (Major interaction), baclofen or an MAOI antidepressant (Moderate interactions). These are the documented risks we can confirm.
The bottom line
Scorecard at a glanceFully disclosed formula with some supporting evidence behind its ingredients' uses. Major medication interactions have been identified, and safety information is well characterized.
DLPA may be worth considering if you're exploring it for vitiligo under professional guidance. If you take levodopa, baclofen, or an older antidepressant (MAOI), this product isn't a good fit — talk with your pharmacist first.
People with PKU must avoid it entirely. Run your full medication list through the interaction checker below before starting.
Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI
Assessment coverage: 1 of 1 active ingredient matched to our full ingredient reviews (monographs). Based on the product label dated Oct 24, 2024.
This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed
General information
Key facts about DLPA 660, straight from the product label.
| Brand | Earthborn Elements |
|---|---|
| Net contents | 200 Capsule(s) |
| Market status | On market |
| Date entered into DSLD | Oct 24, 2024 |
| DSLD ID | 319546 |
| Product type | Amino Acid/protein |
| Supplement form | Capsule |
| Dietary claims / uses | All Other |
| Intended target group(s) | Adult (18 - 50 Years) |
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.
Supplement Facts
The label details for DLPA 660 by Earthborn Elements, sourced from the NIH Dietary Supplement Label Database.
Tap any ingredient to jump to its full detail below.
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Suggested/Recommended/Usage/Directions
Suggested use: Take 2 capsules 1 to 2 times daily, preferably with meals, or as directed by a physician. Take with at least 8 oz of liquid.
General Statements
Questions? Concerns? Scan this code with your phone's camera to chat with us online and get 20% coupon for your next Amazon Earthborn Elements order!
FDA Statement of Identity
Dietary Supplement
Is this label outdated? Report a formula or label change and our pharmacy team will review it.
DLPA 660 by Earthborn Elements label
The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.
Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.
View the full label (PDF)The Ingredients in DLPA 660 by Earthborn Elements
This is the 1 active ingredient this product is made of. Select it to open its full monograph.
Serving size2 Capsule(s) Dosage formCapsule Servings per container100 Amounts shown are per serving.
DLPA
Interacts with16 drugs
Phenylalanine is an essential amino acid the body uses to make brain chemicals like dopamine and norepinephrine. Some people take it for mood, vitilig...
DLPA monograph & interactionsOther (inactive) ingredients: Gelatin. These complete the product’s ingredient list but are not active constituents.
DLPA 660 by Earthborn Elements Drug Interactions
HelloPharmacist Interaction Report
DLPA 660 by Earthborn Elements interacts with several medications, with the most serious concern being levodopa (Parkinson's medication).
DLPA can significantly reduce how well levodopa works in your brain by competing with it for transport, which may worsen tremor, stiffness, and the "on-off" effect that Parkinson's patients experience.
Read the full breakdown — every affected drug type, severity by severity
Moderate interactions are documented with baclofen (a muscle relaxer) — DLPA can lower how much baclofen your body absorbs — and with monoamine oxidase inhibitors (MAOIs), an older class of antidepressants. The MAOI interaction is theoretical but carries a real risk: DLPA breaks down into tyrosine, which could prevent the body from clearing tyramine normally and raise blood pressure dangerously.
Altogether, these interactions span 16 individual medications. If you take any of these drug types, check your specific medications with the tool below before starting DLPA.
Check your own medications below · Editorial policy · How we use AI
Want to check YOUR meds against DLPA 660?
Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.
Go to the checkerIngredients driving the most interactions
Individual Drug Interactions
The ingredients in DLPA 660 interact with 16 drugs. Click any drug to see the details.
1 of the 1 ingredient in DLPA 660 interact with drugs. Each result below shows which ingredient is responsible. DLPA
Benserazide, LevodopaMadopar, Prolopa
How Benserazide, Levodopa interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaLevodopa Major
Interaction Summary
Phenylalanine, especially in high doses, can reduce the effectiveness of levodopa.
Read the full Dlpa + Benserazide, Levodopa interactionCarbidopa, LevodopaDhivy, Rytary, Sinemet, Sinemet CR
How Carbidopa, Levodopa interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaLevodopa Major
Interaction Summary
Phenylalanine, especially in high doses, can reduce the effectiveness of levodopa.
Read the full Dlpa + Carbidopa, Levodopa interactionCarbidopa, Levodopa, EntacaponeStalevo
How Carbidopa, Levodopa, Entacapone interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaLevodopa Major
Interaction Summary
Phenylalanine, especially in high doses, can reduce the effectiveness of levodopa.
Read the full Dlpa + Carbidopa, Levodopa, Entacapone interactionLevodopaInbrija, Larodopa
How Levodopa interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaLevodopa Major
Interaction Summary
Phenylalanine, especially in high doses, can reduce the effectiveness of levodopa.
Read the full Dlpa + Levodopa interactionLevodopa, CarbidopaDuodopa
How Levodopa, Carbidopa interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaLevodopa Major
Interaction Summary
Phenylalanine, especially in high doses, can reduce the effectiveness of levodopa.
Read the full Dlpa + Levodopa, Carbidopa interactionAmphetamineAdensys XR-ODT, Adzenys ER, Dyanavel XR, Mydayis
How Amphetamine interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Amphetamine interactionBaclofenFleqsuvy, Lioresal, Lyvispah, Ozobax
How Baclofen interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaBaclofen Moderate
Interaction Summary
Concomitant intake of phenylalanine may reduce the intestinal absorption of baclofen.
Read the full Dlpa + Baclofen interactionIsocarboxazidMarplan
How Isocarboxazid interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Isocarboxazid interactionLioresalLioresal Injection
How Lioresal interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaBaclofen Moderate
Interaction Summary
Concomitant intake of phenylalanine may reduce the intestinal absorption of baclofen.
Read the full Dlpa + Lioresal interactionMoclobemideManerix, Moclobemide
How Moclobemide interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Moclobemide interactionOzanimod HydrochlorideZeposia
How Ozanimod Hydrochloride interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Ozanimod Hydrochloride interactionPhenelzine SulfateNardil
How Phenelzine Sulfate interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Phenelzine Sulfate interactionRasagilineAzilect
How Rasagiline interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Rasagiline interactionSafinamide MesylateXadago
How Safinamide Mesylate interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Safinamide Mesylate interactionSelegilineCarbex, Eldepryl, Emsam, Zelapar
How Selegiline interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Selegiline interactionTranylcypromineParnate
How Tranylcypromine interacts with DLPA 660 — through 1 ingredient. Tap an ingredient for the detail:
DlpaMonoamine Oxidase Inhibitors (maois) Moderate
Interaction Summary
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
Read the full Dlpa + Tranylcypromine interactionEach ingredient & the kinds of drugs it affects
For each ingredient in DLPA 660 with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.
DLPA
Levodopa
Phenylalanine, especially in high doses, can reduce the effectiveness of levodopa.
Phenylalanine competes with levodopa for carrier-mediated transport into the brain. The resulting reduction in levels of levodopa in the brain can exacerbate tremor, rigidity, and the "on-off" phenomenon in patients with Parkinson disease.
Baclofen
Concomitant intake of phenylalanine may reduce the intestinal absorption of baclofen.
Phenylalanine and baclofen share the same intestinal carrier for absorption; phenylalanine competitively inhibits the absorption of baclofen, reducing its plasma levels.
Monoamine Oxidase Inhibitors (Maois)
Theoretically, concomitant use of L-phenylalanine and non-selective MAOIs might increase the risk of hypertensive crisis.
L-phenylalanine is metabolized to tyrosine. Some evidence suggests that L-phenylalanine, given with the non-selective MAOI pargyline, might prevent the elimination of tyramine, increasing the risk of hypertensive crisis. However, this was not reported in a small number of patients when using L-phenylalanine with the partially selective MAO-B inhibitor, selegiline.
Brand information
Manufacturer and brand details for DLPA 660, from the product label.
Earthborn Elements
See all Earthborn Elements products- Name
- Earthborn Elements
- Street Address
- 9450 SW Gemini Dr #49936
- City
- Beaverton
- State
- Oregon
- ZipCode
- 97008
- Web Address
- Earthbornelements.com
DLPA 660 by Earthborn Elements: Common Questions
Does DLPA 660 by Earthborn Elements interact with any medications?
How can one product interact with so many drugs?
Where does this information come from?
Can I take DLPA while I'm pregnant?
Can I take DLPA while breastfeeding?
Who should not take DLPA?
What side effects might I notice?
Does DLPA work for ADHD?
What is DLPA used for?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Not sure if DLPA 660 is safe with your meds?
Our pharmacists answer your medication & supplement questions — free.
Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.
The Full Monographs Behind DLPA 660’s Ingredients
Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.
Sources & How We Checked
DLPA 660's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.
- NIH Dietary Supplement Label Database (DSLD) — The official product label on file for this supplement.
- Natural Medicines (Therapeutic Research Center) — Evidence-graded clinical reference behind the ingredient interaction data.
Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.
The 23 references behind this product’s interaction data
Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.
Phenylalanine 23 references
- Rouse B, Azen C, Koch R, et al. Maternal phenylketonuria collaborative Study (MPKUCS) offspring: facial anomalies, malformations, and early neurological sequelae. Am J Med Genet 1997;69:89-95. DOI
- Sturtevant FM. Use of aspartame in pregnancy. Int J Fertil 1985;30:85-7.
- Silkaitis RP, Mosnaim AD. Pathways linking L-phenylalanine and 2-phenylethylamine with p-tyramine in rabbit brain. Brain Res 1976;114:105-15.
- Lehmann WD, Theobald N, Fischer R, Heinrich HC. Stereospecificity of phenylalanine plasma kinetics and hydroxylation in man following oral application of a stable isotope-labelled pseudo-racemic mixture of L- and D-phenylalanine. Clin Chim Acta 1983;128 PubMed
- Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. Neuropsychopharmacology 1997;16:136-46. PubMed
- Siddiqui AH, Stolk LM, Bhaggoe R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology 1994;88:215-8. PubMed
- Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 1984;59:81-7. PubMed
- Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8. PubMed
- Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-37. PubMed
- Juncos JL, Fabbrini G, Mouradian MM, et al. Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 1987;44:1003-5. PubMed
- Eriksson T, Granerus AK, Linde A, et al. "On-off" phenomenon in Parkinson's disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38:1245-8. PubMed
- Baker GB, Bornstein RA, Rouget AC, et al. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol Psychiatry 1991;29:15-22.. PubMed
- Wood DR, Reimherr FW, Wender PH. Treatment of attention deficit disorder with DL-phenylalanine. Psychiatry Res 1985;16:21-6.. PubMed
- Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, DC: National Academy Press, 2002. Available at: http://www.n
- Cederbaum S. Phenylketonuria: an update. Curr Opin Pediatr 2002;14:702-6. PubMed
- Cejudo-Ferragud, E., Nacher, A., Polache, A., Cercos-Fortea, T., Merino, M., and Casabo, V. G. Evidence of competitive inhibition for the intestinal absorption of baclofen by phenylalanine. Int J of Pharm (Amsterdam) 1996;132:63-69. DOI
- Fischer, E., Heller, B., Nachon, M., and Spatz, H. Therapy of depression by phenylalanine. Preliminary note. Arzneimittelforschung. 1975;25(1):132.
- Beckmann, H., Strauss, M. A., and Ludolph, E. Dl-phenylalanine in depressed patients: an open study. J.Neural Transm. 1977;41(2-3):123-134. PubMed
- Sabelli, H. C., Fawcett, J., Gusovsky, F., Javaid, J. I., Wynn, P., Edwards, J., Jeffriess, H., and Kravitz, H. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplem
- Cotzias, G. C., Van Woert, M. H., and Schiffer, L. M. Aromatic amino acids and modification of parkinsonism. N Engl.J Med 2-16-1967;276(7):374-379. PubMed
- Kravitz, H. M., Sabelli, H. C., and Fawcett, J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. J Am Osteopath.Assoc 1984;84(1 Suppl):119-123. DOI
- Mann, J., Peselow, E. D., Snyderman, S., and Gershon, S. D-phenylalanine in endogenous depression. Am.J.Psychiatry 1980;137(12):1611-1612. PubMed
- Katoulis AC, Alevizou A, Bozi E, et al. A randomized, double-blind, vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of solar lentigines. Clin Exp Dermatol 2010;35(5):473-6. PubMed
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC